Browse our latest Cancer Biology articles

Cancer systems immunology is a highly interdisciplinary field that is advancing our ability to understand and predict the complex behavior that orchestrates the interplay between tumors and the immune system.

CHK2 directly binds the AR to mediate transient suppression of AR activity and thus loss of CHK2 function in prostate cancer increases AR activity, DNA damage response and radiation resistance.

DNA-PK and PTEN protect breast cancer cells from lethal replication stress induced by the WEE1 inhibitor AZD1775 and constitute new potential biomarkers for AZD1775 sensitivity.

A novel toxicophore, a 1H-1,2,3-triazole, has been identified in a wide-number of therapeutically-relevant compounds, including two anti-cancer chemotherapeutics, which inhibits mitochondria function and is mechanistically linked to adverse cardiac-cell events.

A structural motif that is found in two cancer drugs may be responsible for their ability to tackle cancers and for the side-effects caused by the drugs.

In lung adenocarcinoma, deleting one glucose transporter, whether it is Glut1 or Glut3 is insufficient, whereas their dual deletion reduces tumor growth.

Anomalous expression of the testis protein ZNF165 in cancer cells promotes assembly of a neomorphic transcriptional complex that modulates transcription of TGFβ target genes to support tumor cell survival.

MARCH5 mediates a pathway driving MCL1 degradation in response to cellular stress, which sensitizes to BH3 mimetic drugs targeting BCLXL and provides a broadly effective therapeutic strategy for solid tumors.

Computational approach to identify reproducible genetic interactions in cancer reveals that they are enriched among protein–protein interaction pairs.

eLife is pleased to present a Special Issue to highlight recent advances in the mechanistic understanding of the immune response to cancer cells.